Investor Presentaiton

ODM-208/MK-5684 for metastatic castration-resistant prostate cancer mCRPC CYP11A inhibitor blocking synthesis of steroids and thus ligands for androgen receptor activation Orion develops ODM-208/MK-5684 in collaboration with MSD Phase II CYPIDES trial ongoing . • First results presented at ASCO-GU 2024 • PSA 50 responses in 55.6% of AR-LBD mutation positive and in 16.7% of AR-LBD mutation negative patients . . • PSA 30 responses in 69.8% of AR-LBD mutation positive and in 30.0% of AR-LBD mutation negative patients • ODM-208 was well-tolerated: the most common treatment- related adverse events were related to adrenal suppression with the rate of hospitalisation for adrenal insufficiency being much lower than in phase 1 when typically higher doses were administered (3.0% vs. 33% respectively). Phase III Omaha1 trial ongoing • Randomised, open-label • • ORION Treatment: ODM-208/MK5684 in combination with HRT compared to an alternative NHA Participants: ~1,200 patients with later-line mCRPC who have failed one prior new hormonal agent (NHA) and one or two prior taxane-based chemotherapies • Primary endpoints: overall survival (OS) and radiographic progression-free survival (rPFS) by AR LBD mutation status Phase III Omaha2a trial ongoing • • Randomised, open-label Treatment: ODM-208/MK5684 in combination with HRT compared to an alternative NHA Participants: 1,500 patients with front-line mCRPC who have. failed one prior NHA • Primary endpoints: overall survival (OS) and rPFS by AR LBD mutation status. 12 Investor Presentation Orion Corporation

View entire presentation